scholarly article | Q13442814 |
P50 | author | Christian Hölscher | Q37831053 |
Olavo Bohrer Amaral | Q42404085 | ||
Jean C Houzel | Q56073526 | ||
Mychael V Lourenco | Q57057252 | ||
José B Carvalheira | Q59450289 | ||
Lício Velloso | Q64745748 | ||
Paula Campello-Costa | Q74182006 | ||
Letícia Forny-Germano | Q80863708 | ||
Sérgio Teixeira Ferreira | Q86818733 | ||
Fernanda De Felice | Q87769550 | ||
Julia R Clarke | Q92209886 | ||
William L. Klein | Q104975865 | ||
Jordano Brito-Moreira | Q106909123 | ||
Theresa R Bomfim | Q106909148 | ||
André F Batista | Q106909159 | ||
Rudimar L Frozza | Q106909168 | ||
P2093 | author name string | Douglas P Munoz | |
Luciana B Sathler | |||
Aristobolo M Silva | |||
Sheila Espírito-Santo | |||
Cesar A Silva | |||
Léo Freitas-Correa | |||
P433 | issue | 6 | |
P921 | main subject | Alzheimer's disease | Q11081 |
TNF | Q18032037 | ||
P304 | page(s) | 831-843 | |
P577 | publication date | 2013-12-01 | |
P1433 | published in | Cell Metabolism | Q1254684 |
P1476 | title | TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys | |
P478 | volume | 18 |
Q55001725 | A New Venue of TNF Targeting. |
Q91973479 | A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease |
Q37087410 | A Systems View of the Differences between APOE ε4 Carriers and Non-carriers in Alzheimer's Disease |
Q35006687 | Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies |
Q97423162 | Activation of GPR40 induces hypothalamic neurogenesis through p38- and BDNF-dependent mechanisms |
Q64285109 | Adiponectin suppresses amyloid-β oligomer (AβO)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-κB signaling pathway |
Q93006380 | Adipose Tissue and Brain Metabolic Responses to Western Diet-Is There a Similarity between the Two? |
Q37724402 | Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station |
Q48262702 | Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates. |
Q35084406 | Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. |
Q61959960 | Amelioration of Aluminum Maltolate-Induced Inflammation and Endoplasmic Reticulum Stress-Mediated Apoptosis by Tannoid Principles of Emblica officinalis in Neuronal Cellular Model |
Q35327172 | Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis |
Q28384947 | Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease |
Q48259811 | Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons |
Q55560479 | Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights. |
Q64074885 | Astrocyte Heterogeneity: Impact to Brain Aging and Disease |
Q46352159 | Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer's Disease Model. |
Q90745617 | Behavioral Abnormalities in Knockout and Humanized Tau Mice |
Q89767521 | Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death |
Q57022699 | Bone protection by inhibition of microRNA-182 |
Q38253639 | Brain alterations and clinical symptoms of dementia in diabetes: aβ/tau-dependent and independent mechanisms |
Q38515312 | Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease |
Q48396253 | Brain-Defective Insulin Signaling Is Associated to Late Cognitive Impairment in Post-Septic Mice. |
Q26739374 | CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection |
Q47928995 | Calcium Dysregulation in Alzheimer's Disease: A Target for New Drug Development |
Q50199042 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects |
Q39445809 | Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism |
Q48152519 | Consequences of gestational diabetes to the brain and behavior of the offspring |
Q39141602 | Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-β Oligomers in Mice. |
Q26765530 | Current Research Therapeutic Strategies for Alzheimer's Disease Treatment |
Q39023028 | Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease |
Q92209534 | Decreased Quality of Life in Individuals with Type 2 Diabetes Mellitus Is Associated with Emotional Distress |
Q54111592 | Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer's disease models. |
Q50206017 | Dissecting Endoplasmic Reticulum Unfolded Protein Response (UPRER) in Managing Clandestine Modus Operandi of Alzheimer's Disease |
Q38195215 | Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases |
Q98177367 | Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions |
Q89265602 | ER Proteostasis Control of Neuronal Physiology and Synaptic Function |
Q59128157 | Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression |
Q33730922 | Endoplasmic reticulum stress and inflammation in the central nervous system |
Q30841556 | Endoplasmic reticulum stress-induced neuronal inflammatory response and apoptosis likely plays a key role in the development of diabetic encephalopathy |
Q92237102 | Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells |
Q91636820 | Exercise-Induced Cognitive Improvement Is Associated with Sodium Channel-Mediated Excitability in APP/PS1 Mice |
Q90929504 | Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models |
Q52142981 | Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse. |
Q39393398 | Fine-tuning PERK signaling for neuroprotection. |
Q38606226 | Hippocampal insulin resistance and cognitive dysfunction |
Q40278876 | IRE1 signaling exacerbates Alzheimer's disease pathogenesis |
Q38247021 | IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity |
Q27003841 | Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease |
Q26773657 | Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease |
Q64262753 | Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes |
Q59808617 | Insulin Resistance in Alzheimer's Disease |
Q64092659 | Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease |
Q89542342 | Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease |
Q48252699 | Integrated Stress Response: Connecting ApoE4 to Memory Impairment in Alzheimer's Disease. |
Q48268984 | Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice |
Q28394967 | Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors |
Q48481506 | Intranasal Insulin Administration Ameliorates Streptozotocin (ICV)-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Memory Impairment in Rats |
Q92964508 | Involvement of insulin receptor substrates in cognitive impairment and Alzheimer's disease |
Q38938961 | Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal |
Q38561865 | Linking insulin with Alzheimer's disease: emergence as type III diabetes |
Q41899669 | Memory loss in Alzheimer's disease: are the alterations in the UPR network involved in the cognitive impairment? |
Q47140950 | Mild endoplasmic reticulum stress ameliorates lipopolysaccharide-induced neuroinflammation and cognitive impairment via regulation of microglial polarization |
Q38974881 | Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology |
Q92649463 | Multi-Loop Model of Alzheimer Disease: An Integrated Perspective on the Wnt/GSK3β, α-Synuclein, and Type 3 Diabetes Hypotheses |
Q60046048 | N-Acetylcysteine Prevents the Spatial Memory Deficits and the Redox-Dependent RyR2 Decrease Displayed by an Alzheimer’s Disease Rat Model |
Q90228110 | Natural Products as Modulators of the Proteostasis Machinery: Implications in Neurodegenerative Diseases |
Q90236862 | Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases |
Q47120381 | Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers. |
Q26866194 | New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases |
Q90305669 | Novel roles of ER stress in repressing neural activity and seizures through Mdm2- and p53-dependent protein translation |
Q47641854 | PKR Inhibition Rescues Memory Deficit and ATF4 Overexpression in ApoE ε4 Human Replacement Mice |
Q43143483 | PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model |
Q42371247 | PKR involvement in Alzheimer's disease |
Q54978322 | PKR modulates abnormal brain signaling in experimental obesity. |
Q61449861 | PKR: A Kinase to Remember |
Q38903340 | Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity |
Q37614594 | Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer's Therapy? |
Q47845996 | Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides |
Q38682450 | Regulation of Posttranslational Modifications of HMGB1 During Immune Responses |
Q28081526 | Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory |
Q92703384 | Serine Phosphorylation of IRS1 Correlates with Aβ-Unrelated Memory Deficits and Elevation in Aβ Level Prior to the Onset of Memory Decline in AD |
Q38934950 | Shared Genetic Etiology between Type 2 Diabetes and Alzheimer's Disease Identified by Bioinformatics Analysis |
Q26784170 | Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline |
Q59795046 | Soluble Fibrinogen Triggers Non-cell Autonomous ER Stress-Mediated Microglial-Induced Neurotoxicity |
Q35643397 | Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease |
Q48524916 | Stimulation of TLR4 Attenuates Alzheimer's Disease-Related Symptoms and Pathology in Tau-Transgenic Mice |
Q28077671 | Synaptopathies: synaptic dysfunction in neurological disorders - A review from students to students |
Q54977832 | The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. |
Q39410246 | The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance |
Q39182975 | The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease |
Q61448813 | The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer's Disease |
Q26751165 | The association between PGC-1α and Alzheimer's disease |
Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
Q33600053 | The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease |
Q39021127 | The neuronal insulin receptor in its environment |
Q41828232 | The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease |
Q38823805 | Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia |
Q48338374 | Training Microglia to Resist Alzheimer's Disease |
Q36487154 | Translational control in synaptic plasticity and cognitive dysfunction |
Q38928927 | Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation |
Q33704278 | Tumor necrosis factor α Inhibition for Alzheimer's Disease |
Q34475073 | d-serine levels in Alzheimer's disease: implications for novel biomarker development |
Q37369248 | eIF2α phosphorylation controls thermal nociception |
Search more.